title: Esophagitis associated with the use of alendronate.
abstract: BACKGROUND
  Alendronate, an aminobisphosphonate and a selective inhibitor of osteoclast-mediated bone resorption, is used to treat osteoporosis in postmenopausal women and Paget's disease of bone. Aminobiphosphonates can irritate the upper gastrointestinal mucosa.
  
  
  METHODS
  We describe three patients who had severe esophagitis shortly after starting to take alendronate and also analyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveillance.
  
  
  RESULTS
  As of March 5, 1996, alendronate had been prescribed for an estimated 475,000 patients worldwide, and 1213 reports of adverse effects had been received. A total of 199 patients had adverse effects related to the esophagus; in 51 of these patients (26 percent), including the 3 we describe in case reports, adverse effects were categorized as serious or severe. Thirty-two patients (16 percent) were hospitalized, and two were temporarily disabled. Endoscopic findings generally indicated chemical esophagitis, with erosions or ulcerations and exudative inflammation accompanied by thickening of the esophageal wall. Bleeding was rare, and stomach or duodenal involvement unusual. In patients for whom adequate information was available, esophagitis seemed to be associated with swallowing alendronate with little or no water, lying down during or after ingestion of the tablet, lying down during or after ingestion of the tablet, continuing to take alendronate after the onset of symptoms, and having preexisting esophageal disorders.
  
  
  CONCLUSIONS
  Alendronate can cause chemical esophagitis, including severe ulcerations, in some patients. Recommendations to reduce the risk of esophagitis include swallowing alendronate with 180 to 240 ml (6 to 8 oz) of water on arising in the morning, remaining upright for at least 30 minutes after swallowing the tablet and until the first food of the day has been ingested, and discontinuing the drug promptly if esophageal symptoms develop.
authors.affiliation: Division of Gastroenterology, Mayo Clinic and Foundation, Rochester, MN55905, USA.
authors.forename: P C
authors.initials: PC
authors.lastname: de Groen
authors.forename: D F
authors.initials: DF
authors.lastname: Lubbe
authors.forename: L J
authors.initials: LJ
authors.lastname: Hirsch
authors.forename: A
authors.initials: A
authors.lastname: Daifotis
authors.forename: W
authors.initials: W
authors.lastname: Stephenson
authors.forename: D
authors.initials: D
authors.lastname: Freedholm
authors.forename: S
authors.initials: S
authors.lastname: Pryor-Tillotson
authors.forename: M J
authors.initials: MJ
authors.lastname: Seleznick
authors.forename: H
authors.initials: H
authors.lastname: Pinkas
authors.forename: K K
authors.initials: KK
authors.lastname: Wang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate; D004164:Diphosphonates / Q000009:adverse effects*; D004941:Esophagitis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D011859:Radiography; D014456:Ulcer / Q000139:chemically induced / Q000000981:diagnostic imaging
chemical_list: D004164:Diphosphonates; D019386:Alendronate